Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study. (Q50663391)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 February 2016

Language	Label	Description	Also known as
English	Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study.	scientific article published on 29 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Maintenance of Cognitive Performance and Mood for Individuals with Alzheimer's Disease Following Consumption of a Nutraceutical Formulation: A One-Year, Open-Label Study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Alzheimer's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ruth Remington

1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Cynthia Bechtel

2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

David Larsen

3

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Annemarie Samar

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Robert Page

5

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Christopher Morrell

6

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Thomas B Shea

7

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

publication date

29 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Journal of Alzheimer's Disease

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

51

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

991-995

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Preventing Alzheimer's disease

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A potential design flaw of randomized trials of vitamin supplements

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer's disease: a placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

CLOX: an executive clock drawing task

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Clinical validity of the Mattis Dementia Rating Scale in detecting dementia of the Alzheimer type: a double cross-validation and application to a community-dwelling sample

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Towards an aging-specific cognitive phenotype: the freedom house study

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Disease progression meta-analysis model in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Mediterranean Diet and Risk of Dementia

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants

1 reference

https://api.crossref.org/works/10.3233%2FJAD-151098

21 January 2018

Identifiers

10.3233/JAD-151098

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/26967219

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50663391&oldid=1760584120"